BioLineRx(BLRX) - 2023 Q3 - Earnings Call Transcript

It does. I'd like to add something. Joe, IÂ'd like to add something -- I just I'm sorry, I sorry to interrupt you. I just wanted to add, first of all, hi, good to speak to you. But I do want to add, we mentioned the gene therapy in the sickle cell disease area. And Joe Pantginis Phil Serlin Of course, I'm not ruling out us potentially taking this forward ourselves depending on the situation. but it's likely in a very significant indication like this. And when we're talking about PDAC, we're not only talking ...